Acta Med. 2002, 45: 85-88
https://doi.org/10.14712/18059694.2019.60
Prophylaxis Against Anthrax
References
1. PS, Plotkin SA, Bumford FH, Atchison MM. An epidemic of inhalation anthrax: the firs in the twentieth century. II. Epidemiology. Am J Hyg 1960; 72:6–23.
2. PS, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. Field evaluation of a human anthrax vaccine. Am J Public Health 1962; 52:632–45.
<https://doi.org/10.2105/AJPH.52.4.632>
3. Brachman PS, Friedlander AM. Anthrax. In: Plotkin SA, Mortimer EA, eds. Vaccines. 2nd ed. Philadelphia, PA: WB Saunders Company, 1994:729–39.
4. CDC. Bioterrorism alleging use of anthrax and interim guidelines for management – US, 1998, MMWR 1999; 48:69–74.
5. HM, Belton FC, Henderson DW. The use of anthrax antigen to immunise man and monkey. Lancet 1956; 476(September 8):9.
6. M, Aydin N. Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis 1991; 23:333–5.
<https://doi.org/10.3109/00365549109024319>
7. DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278:399–411.
<https://doi.org/10.1001/jama.1997.03550050061035>
8. AM, Welkos SL, Pitt MLM, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993; 167:1239–42.
<https://doi.org/10.1093/infdis/167.5.1239>
9. DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg 1956; 54:28–36.
<https://doi.org/10.1017/S0022172400044272>
10. Iowa Persian Gulf Study Group. Self-reported illness and health status among Gulf War veterans: a population-based study. JAMA 1997; 277:238–45.
11. BE, Fellowx PF, Pitt MLM, et al. Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys. Salisbury Medical Bulletin (September 19 –21) 1995;87(suppl.):125–6.
12. Jemski JV. Respiratory virulence of Pasteurella tularensis Schu S4 strain, for man, monkey and guinea pig. April 15, 1963. DTIC recovery no. AD 498–288.
13. NF, Scott RJD, Turnbull PCB. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med Bull (April 11–13) 1990; 68(suppl):95–8.
14. M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outhbreak of 1979. Science 1994; 266:1202–7.
<https://doi.org/10.1126/science.7973702>
15. RN, Kadul PJ, Cluff LE. Intensive immunization of man: evaluation of possible adverse consequences. Ann Intern Med 1965; 63:44–57.
<https://doi.org/10.7326/0003-4819-63-1-44>
16. ProMED-mail post. Anthrax, Human – USA: antibicrobial susceptibility, October 22, 2001.
17. M, Wright GG. Studies on immunity in anthrax. X. Gel-adsorbed protective antigen for immunization in man. J Bacteriol 1963; 85:230–6.
18. M, Manning LC, Lynch JW, Barclay E, Abelow I, Whright GG. Large-scale production of protective antigen of Bacillus anthracis in aerobic culturec. Appl Microbiol 1963; 11:330–4.
19. M. The use of anthrax vaccines prepared from avirulent (unencapsulated) variants of Bacillus anthracis. Onderstepoort J Vet Sci An Ind 1939; 13:307–12.
20. HB, Boor AK. An antigen prepared in vitro effective for immunization against anthrax. III. Immunisation of monkeys against anthrax. J Infect Dis 1954; 73:387–91.
21. PCB, Broster MG, Carman JA, Manchee RJ, Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 1986; 52:356–63.
